• Single-center (Montefiore Medical Center, Bronx, NY, USA), retrospective chart analysis of 795 patients aged
    ≥18 years with BMI >40 kg/m² (range 40-88) who were prescribed apixaban, rivaroxaban, or warfarin for VTE or AF*
    • Overall 2699 patients were identified; 1904 patients with VTE + AF, or indications for OAC other than VTE or AF were excluded
  • Measured recurrent VTE, stroke, and bleeding from the first Rx date (March 1, 2013-March 1, 2017) to the earliest of thrombotic event, medication d/c, death, or end of study (June 30, 2017)
1|2